基于WHO药物警戒数据库的不良事件特征匹配用于雷诺现象的药物重定位
本研究利用WHO药物警戒数据库,通过不良事件特征匹配探索雷诺现象的药物重定位。研究者筛选与红斑性肢痛症(雷诺现象的相反不良事件)相关的药物,并定义二线雷诺现象推荐药物的不良事件特征,进行层次聚类分析。结果发现阿仑单抗和富马酸可能对继发性雷诺现象有效。
要点
- 基于不良事件特征匹配可提出雷诺现象的药物重定位假设。
- 阿仑单抗和富马酸与雷诺现象治疗药物具有相似不良事件特征。
- 富马酸正在被研究用于系统性硬化相关肺动脉高压。
核心结论
- 不良事件特征匹配方法提示阿仑单抗和富马酸可能对继发性雷诺现象有效。
研究设计与样本
- 利用WHO药物警戒数据库进行不良事件特征匹配的探索性研究,筛选与红斑性肢痛症相关的药物,并定义14种最具代表性的二线雷诺现象推荐药物不良事件特征。
主要发现
- 层次聚类分析识别出6个聚类,最稳定的聚类包含7种药物。
- 最稳定聚类中5种为二线雷诺现象推荐药物或同类药物:依前列醇、硝苯地平、尼卡地平、拉西地平、伊拉地平。
- 最稳定聚类中另外2种药物为阿仑单抗和富马酸。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Several pharmacological treatments are recommended for Raynaud's phenomenon (RP) secondary to systemic sclerosis, but they only have modest efficacy. A way to efficiently identify new drugs is drug repurposing, which can be based on signature matching. The signature could be derived from chemical structures, pharmacological affinity or adverse event profiles. We propose to use the World Health Organization (WHO) pharmacovigilance database to generate repositioning hypotheses for treatments of RP through adverse event signature matching. METHODS: We first screened all drugs associated with at least 1 case of erythromelalgia, an adverse effect opposite to RP. In parallel, to define the adverse event signature of drugs recommended in secondary RP from the WHO pharmacovigilance database, we selected the 14 most representative adverse drug reactions (ADRs). Lastly, we performed a hierarchical cluster analysis to identify drugs with similar ADR signature to vasodilatory drugs used in RP. RESULTS: In total, 179 drugs were associated with erythromelalgia; they were related to 860 334 adverse events representative of RP drugs in the WHO pharmacovigilance database. Hierarchical cluster analysis allowed identification of 6 clusters. The most stable cluster contained 7 drugs, among which 5 are recommended in secondary RP, or pertain to the same drug class: epoprostenol, nifedipine, nicardipine, lacidipine and israpidine. The 2 remaining drugs were alemtuzumab and fumaric acid. CONCLUSION: Our ADR signature matching approach suggests that alemtuzumab and fumaric acid could be effective treatments of secondary RP. The latter is currently being investigated as a treatment of pulmonary hypertension in systemic sclerosis.
引用
- Zaza P, Matthieu R, Jean-Luc C, et al. Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2020. PMID: 32337731. doi:10.1111/bcp.14322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。